{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:34:10Z","timestamp":1793205250370,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024253","name":"Western Australian Future Health and Innovation Fund, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hlc.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:12:33Z","timestamp":1757085153000},"page":"1089-1097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-7314","authenticated-orcid":false,"given":"Nick S.R.","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"McFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Shedden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8100-6209","authenticated-orcid":false,"given":"P. Gerry","family":"Fegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Puttagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0880-8501","authenticated-orcid":false,"given":"Sharon","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8007-2480","authenticated-orcid":false,"given":"Richard","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramyasuda","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-740X","authenticated-orcid":false,"given":"Girish","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2025.07.007_bib1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.07.007_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2025.07.007_bib3","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2025.07.007_bib4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.07.007_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41581-025-00931-8","article-title":"Risk-directed management of chronic kidney disease","volume":"21","author":"Blum","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2025.07.007_bib6","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hlc.2025.07.007_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib11","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.07.007_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.07.007_bib15","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2025.07.007_bib16","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019\u20132020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.hlc.2025.07.007_bib17","article-title":"Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data","volume":"43","author":"Neuen","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.hlc.2025.07.007_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamainternmed.2021.4813","article-title":"Accounting for age in the definition of chronic kidney disease","volume":"181","author":"Liu","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.hlc.2025.07.007_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102426","article-title":"Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study","volume":"68","author":"Forbes","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.hlc.2025.07.007_bib22","article-title":"The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations","volume":"18","author":"Liabeuf","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.hlc.2025.07.007_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis","volume":"174","author":"Karagiannis","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.hlc.2025.07.007_bib24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.hlc.2025.07.007_bib25","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ekir.2019.07.014","article-title":"Achievement of low-density lipoprotein cholesterol targets in CKD","volume":"4","author":"Massy","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.hlc.2025.07.007_bib26","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2025.07.007_bib27","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2025.07.007_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.07.007_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MED.0000000000000594","article-title":"Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines","volume":"28","author":"Lan","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.hlc.2025.07.007_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5694\/mja2.12035","article-title":"Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis","volume":"210","author":"Brieger","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.07.007_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database","volume":"38","author":"Fried","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hlc.2025.07.007_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2025.07.007_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11886-024-02174-8","article-title":"Learnings from implementation strategies to improve lipid management","volume":"27","author":"Lan","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.hlc.2025.07.007_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2024.151520","article-title":"Challenges and strategies in implementing novel kidney protective and cardioprotective therapies in patients with diabetes and kidney disease","volume":"44","author":"Limonte","year":"2024","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.hlc.2025.07.007_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hlc.2025.07.007_bib36","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2025.07.007_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hlc.2025.07.007_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625015549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625015549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:03:45Z","timestamp":1762545825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950625015549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1443950625015549"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2025.07.007","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}